Putting together the psoriasis puzzle: an update on developing targeted therapies
about
Lifting the silver flakes: the pathogenesis and management of chronic plaque psoriasisImmune Pathways in Atopic Dermatitis, and Definition of Biomarkers through Broad and Targeted TherapeuticsIL-17 drives psoriatic inflammation via distinct, target cell-specific mechanisms.Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23/IL-17 axis.Oxazolone-induced contact hypersensitivity reduces lymphatic drainage but enhances the induction of adaptive immunity.IL-6 Signaling in Myelomonocytic Cells Is Not Crucial for the Development of IMQ-Induced PsoriasisProviding Guidance for Patients With Moderate-to-Severe Psoriasis Who Are Candidates for Biologic Therapy: Role of the Nurse Practitioner and Physician Assistant.Langerin(neg) conventional dendritic cells produce IL-23 to drive psoriatic plaque formation in mice.Three-dimensional model of mouse epidermis for experimental studies of psoriasis.Overexpression of Glucocorticoid-induced Leucine Zipper (GILZ) increases susceptibility to Imiquimod-induced psoriasis and involves cutaneous activation of TGF-β1.Psoriasis and Psoriatic Arthritis.Investigational drugs for treating psoriatic arthritis.The role of the ubiquitin-editing enzyme A20 in diseases of the central nervous system and other pathological processes.Impact of pregnancy and oestrogen on psoriasis and potential therapeutic use of selective oestrogen receptor modulators for psoriasis.Oxidative stress in psoriasis and potential therapeutic use of antioxidants.Tumour necrosis factor-α plays a significant role in the Aldara-induced skin inflammation in mice.Ubiquitination of RORγt at Lysine 446 Limits Th17 Differentiation by Controlling Coactivator Recruitment.Exposure to Carbon Ions Triggers Proinflammatory Signals and Changes in Homeostasis and Epidermal Tissue Organization to a Similar Extent as Photons.Cetuximab and panitumumab in a patient with colon cancer and concomitant chronic skin disease: a potential beneficial effect on psoriasis vulgaris.Cutting edge: ABIN-1 protects against psoriasis by restricting MyD88 signals in dendritic cells.Regulation of Th17 Differentiation by IKKα-Dependent and -Independent Phosphorylation of RORγt.Primary aldosteronism patients show skin alterations and abnormal activation of glucocorticoid receptor in keratinocytes.IL-35 recombinant protein reverses inflammatory bowel disease and psoriasis through regulation of inflammatory cytokines and immune cells.Essential Role of CARD14 in Murine Experimental Psoriasis.Biological therapy induces expression changes in Notch pathway in psoriasis.Positive effects of hydrogen-water bathing in patients of psoriasis and parapsoriasis en plaques.Epidermal glucocorticoid and mineralocorticoid receptors act cooperatively to regulate epidermal development and counteract skin inflammation.
P2860
Q24626968-45753E3A-0775-4718-A086-FB6AF52D1A8CQ26799532-ACB54CFE-A242-4902-A7E8-D5B8A961EA4BQ34082705-B8D5F55B-15D2-4CD5-B7E6-0B810BA89ED1Q34218639-38E88F40-DEEE-422A-9AE5-D8E175C810D8Q35184089-C85D7FAD-6C53-4CB6-B7D0-ED119B63A869Q35964908-4AF9B321-659B-42A4-B9CE-851BF290CDE4Q36628064-9A7D7856-239C-4BE9-AF16-6E2F972DD7A2Q36967801-63646EE2-D69F-4704-992C-AB3A33112E38Q37475600-00E5651B-53CF-4C07-AEF4-E4957AD748D4Q37488232-1AF1EA5A-D7EB-4134-8BBE-064D4CE1BF13Q37723047-0422AC95-07C0-44C5-B760-07AE38F89A63Q38206551-F1B07921-A0F8-457E-83E3-083998326F46Q38540498-8B33222F-C452-4A2C-ADEB-EA2AD4136FF6Q38807000-54C881A7-9391-4A02-8D6E-D285EC1B5D62Q38813221-F84FED41-27AD-4CA7-B7E5-69322CE59BFCQ38937859-352CA3CC-7F5C-445B-BF72-13A487461E10Q42376373-6F2B39FB-C5A8-4FC6-B9CB-CBA3A5ECEF3CQ42487654-A41FB4D7-E28E-4CD6-948F-AD10E7C32A37Q42685684-814C14F4-5A7C-4E31-AA39-E955C8B8E72DQ43104786-A6D8C273-4FFE-4B5C-BB8E-94016FDF0979Q43523326-C2BF5EB0-018D-476C-B2C0-5925BAEA69F3Q45567424-B912939B-A670-43DA-B678-CCB5D695FDE3Q47343053-B526DB24-429B-4FE6-B54F-6D0520151B2DQ47390083-414D84F1-E767-463A-A35E-2919718A61CCQ53368019-7B38B9C9-29E2-4427-B1E5-2BD62B5CD542Q55141743-1DD8133A-E4E9-4C9A-8E61-45346B432AB4Q55288969-6835566D-8467-4335-A813-521404E27DB6
P2860
Putting together the psoriasis puzzle: an update on developing targeted therapies
description
2012 nî lūn-bûn
@nan
2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
Putting together the psoriasis puzzle: an update on developing targeted therapies
@ast
Putting together the psoriasis puzzle: an update on developing targeted therapies
@en
Putting together the psoriasis puzzle: an update on developing targeted therapies
@nl
type
label
Putting together the psoriasis puzzle: an update on developing targeted therapies
@ast
Putting together the psoriasis puzzle: an update on developing targeted therapies
@en
Putting together the psoriasis puzzle: an update on developing targeted therapies
@nl
prefLabel
Putting together the psoriasis puzzle: an update on developing targeted therapies
@ast
Putting together the psoriasis puzzle: an update on developing targeted therapies
@en
Putting together the psoriasis puzzle: an update on developing targeted therapies
@nl
P2093
P2860
P3181
P356
P1476
Putting together the psoriasis puzzle: an update on developing targeted therapies
@en
P2093
J. G. Krueger
L. M. Johnson-Huang
M. A. Lowes
P2860
P304
P3181
P356
10.1242/DMM.009092
P407
P577
2012-07-01T00:00:00Z